Novel liver cirrhosis or liver fibrosis marker
A technology for substances and liver diseases, applied in the field of biomedicine, can solve problems such as disagreement on the role of GP73
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0037] Example 1 Comparison of serum GP73, AFP, AFP-L3, and AFP-L3 in the diagnosis of primary liver cancer
[0038] 1) Baseline data of research subjects and samples
[0039] The blood samples came from: 805 cases of hepatitis patients; 2015 cases of liver cirrhosis patients; 1102 cases of liver cancer patients, a total of 3922 patients. The specific information of the patients is shown in Table 1.
[0040] The samples were all serum from clinically confirmed patients. These three clinical samples were provided by the 302nd Hospital of the People's Liberation Army. The patients visited the 302nd Hospital of the People's Liberation Army from December 2013 to December 2014.
[0041] 2) Statistical methods
[0042] The SPSS21.0 (SPSS, Chicago, Illinois, USA) statistical software was used for statistical analysis, the continuous variable was selected according to its distribution characteristics, and the quantitative data approximately obeying the normal distribution was used ...
Embodiment 2
[0052] Example 2 Distribution characteristics of serum GP73, AFP, and AFP-L3 (%) in patients with hepatitis, liver cirrhosis and liver cancer
[0053] The research objects and statistical methods are the same as in Example 1. In the experiment, the change trend of AFP, AFP-L3(%) and GP73 in patients with hepatitis, cirrhosis and liver cancer was described by interquartile range. The results showed that the change trend of GP73 in hepatitis, cirrhosis and liver cancer was more obvious. However, liver cancer cannot be distinguished from patients with hepatitis and cirrhosis. AFP and AFP-L3(%) only change significantly in patients with liver cancer, which can well distinguish liver cancer from patients with hepatitis and cirrhosis. See table 3.
[0054] Table 3 Interquartile range of GP73, AFP, AFP-L3 (%) in patients with hepatitis, cirrhosis and liver cancer
[0055]
Embodiment 3
[0056] Example 3 Comparison of serum GP73 and LSM, FIB4, APRI in the diagnosis of liver cirrhosis
[0057] The research objects and statistical methods are the same as in Example 1.
[0058] The results of this part show that the sensitivity and specificity of GP73 in diagnosing liver cirrhosis are 83.97% and 93.54%, respectively, and the area under the curve is 0.927 (95% CI, 0.917-0.937) ( figure 2 ), its diagnostic value is better than that of LSM, FIB-4 index, and platelet (PLT) ratio index APRI of liver stiffness, as shown in Table 4, which shows that GP73 has a strong ability to distinguish patients with liver cirrhosis.
[0059] Table 4 Diagnostic value of GP73, LSM, APRI and FIB4 for liver cirrhosis
[0060]
PUM
Property | Measurement | Unit |
---|---|---|
molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com